While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with onli ...

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...